Results 131 to 140 of about 4,947,726 (309)

National Drugs Advisory Board annual report 1975

, 1975
By the end of 1975. the National Drugs Advisory Board had 15 months of experience in the management of mandatory licensing systems for medicinal products and for manufacturers of pharmaceuticals in Ireland. With few exceptions.
National Drugs Advisory Board (NDAB)
core  

Reports of side effects associated with the use of drugs 1982 [PDF]

, 1982
The National Drugs Advisory Board received 540 reports during 1982 from which 1051 side-effects were reported. 39% of the reactions received occurred in association with drugs affecting the central nervous system, over half concerned analgesics, 18% of
National Drugs Advisory Board (NDAB)
core  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México

Cadernos de Saúde Pública
Para la Organización Mundial de la Salud (OMS) la accesibilidad y la disponibilidad de los medicamentos es un tema central al cual le ha dedicado una gran atención.
Raúl E. Molina-Salazar, José F. Rivas-Vilchis   +1 more
doaj  

Review of drug financing and expenditure in Uganda : sustainability and improved access to essential medicines [PDF]

, 2006
Includes bibliographical references (leaves 73-80).Drugs are an important factor of production in health care. They constitute a significant proportion of health care expenditure in both developed and developing countries rendering financing of drugs an ...
Kikule, Kate
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

The evidence-informed decision-making process of the National Essential Medicines List Committee and Essential Drugs Programme

Journal of the Colleges of Medicine of South Africa
Amanda Brewer, Janine Jugathpal, Kim MacQuilkan, Marc Blockman, Andrew Gray, Tamara Kredo, Reneé de Waal, Lesley Robertson   +7 more
doaj   +1 more source

East and Central African essential drugs programmes management meeting, Lilongwe/Salima, Malawi, 20-24 June 1994

, 1994
ONLINEWHO/DAP/94.20.
WHO Action Programme on Essential Drugs
core  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source